$SCPS News

Last published 3y ago

3y agoSCPSScopus BioPharma's Subsidiary — Duet BioTherapeutics — Presents Compelling New Data for a Novel Treatment for Malignant Glioma at 38th Annual Meeting of the Society for Immunotherapy of CancerGlobeNewswireDUET-102 in Combination with PD-1 Blockade Demonstrates Significant Anti-Tumor Activity in Models of Malignant Glioma Data Suggests Benefits of Combinations of DUET-102 with Other T-Cell Based Immunotherapies, such as
3y agoSCPSScopus BioPharma's Subsidiary — Duet BioTherapeutics — to Present at the 38th Annual Meeting of the Society for Immunotherapy of CancerGlobeNewswireNEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (OTCQB: "SCPS"), a biotechnology company developing transformational therapeutics for serious diseases with significant unmet medical need, and its
4y agoSCPSScopus BioPharma's Subsidiary — Duet BioTherapeutics — Announces Key Scientific Data to be Presented at the 37th Annual Meeting and Exposition of the Society for Immunotherapy of CancerGlobeNewswireNEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: "SCPS"), a biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, and its
4y agoSCPSScopus Biopharma Completes Recapitalization Designed To Enhance Shareholder ValueGlobeNewswireWarrants to Purchase Approximately 21 Million Scopus Shares Eliminated Scopus BioPharma's Pure Play Immuno-Oncology Subsidiary, Duet BioTherapeutics, Independently Valued at $25 Million Scopus Maintains Approximately
4y agoSCPSScopus BioPharma Announces Biotechnology Industry Leader Rejoins Board of DirectorsGlobeNewswireNEW YORK, May 05, 2022 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: "SCPS"), a biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, today announced the appointment of Raphael
4y agoSCPSScopus BioPharma's Subsidiary — Duet BioTherapeutics — to Present at the 3rd Annual STING & TLR-Targeting Therapies SummitGlobeNewswireAlan Horsager, Ph.D., President and Chief Executive Officer of Duet, to Present onTLR9 Activation and STAT3 Inhibition: A Bifunctional Approach to Immuno-Oncology NEW YORK, March 22, 2022 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: "SCPS"), a
4y agoSCPSScopus BioPharma Provides Update Following Annual Meeting of StockholdersGlobeNewswireOverwhelming Majority of Shares Voted by Unaffiliated Stockholderswere in Favor of Scopus' Director Nominees Lasters' Ownership Position and Annual Meeting Results are being Challenged in Court Company Believes Ultimate Outcome of Annual Meeting W
4y agoSCPSDR. MORRIS C. LASTER WINS PROXY CONTEST AS STOCKHOLDERS ELECT HIS NOMINEES TO SCOPUS BIOPHARMA INC. BOARD OF DIRECTORSPR NewswireNEW YORK and JERUSALEM, Jan. 6, 2022 /PRNewswire/ -- Dr. Morris C. Laster ("Dr. Laster"), who, together with other proxy participants, beneficially owns 6,006,000 shares of common stock, par value $0.001, of Scopus BioPharma Inc. (NASDAQ:SCPS) ("Scopus
4y agoSCPSScopus BioPharma Issues Open Letter to Stockholders Detailing Morris Laster's Campaign Against the CompanyGlobeNewswireLatest Legal Claims by Laster Actually Call into Question his Stock Ownership Company Urges Stockholders to Vote "FOR ALL" of the Company's Director Nominees on the WHITE Proxy Card NEW YORK, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc
4y agoSCPSScopus BioPharma Sends Letter Urging Stockholders to Vote "FOR ALL" of the Company's Director Nominees on the WHITE Proxy CardGlobeNewswireCompany's Director Nominees are Highly Qualified and Experienced with Track Records of Guiding Early-Stage Life Science Companies Executing Strategy to Create an Industry-Leading Portfolio of Bi-Functional Cancer Targeting Molecules Recently Raised
4y agoSCPSDr. Morris C. Laster Issues An Open Letter To Scopus BioPharma Inc. Stockholders In Connection With Upcoming Annual MeetingPR NewswireNEW YORK and JERUSALEM, Dec. 6, 2021 /PRNewswire/ -- Dr. Morris C. Laster ("Dr. Laster"), who, together with the other proxy participants, beneficially owns 6,006,000 shares of common stock, par value $0.001 in Scopus BioPharma Inc. (NASDAQ:SCPS) ("Scopu
4y agoSCPSScopus BioPharma Announces $9.75 Million Private Placement Priced At-The-MarketGlobeNewswireNEW YORK, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: "SCPS"), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, today announced it has ent
5y agoSCPSScopus BioPharma Announces Adjournment of Annual Meeting of StockholdersGlobeNewswireNEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: "SCPS") today announced that, on November 5, 2021, its 2021 Annual Meeting of Stockholders (the "Annual Meeting") was adjourned to 11:30 a.m., Eastern time, on Monday, December
5y agoSCPSScopus BioPharma Announces Adjournment of Annual Meeting of StockholdersGlobeNewswireNEW YORK, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: "SCPS"), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, today announced that, on O
5y agoSCPSScopus BioPharma to Present at the LD Micro Main EventGlobeNewswireScopus to present on the recent launch of Duet Therapeutics, its wholly-owned subsidiary focused on immuno-oncology Presentation to include a discussion of preclinical data released at the 17th Annual Meeting of the Oligonucleotide Therapeutics Soci
5y agoSCPSScopus BioPharma Retaining Counsel to Investigate Unusual Market ActivityGlobeNewswireNEW YORK, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: "SCPS"), a clinical-stage biopharmaceutical company, announced today that it is retaining Boies Schiller Flexner LLP to conduct a market manipulation investigation. In the pa
5y agoSCPSScopus BioPharma to Present at MicroCap Rodeo's Fall Harvest Best Ideas ConferenceGlobeNewswireScopus to present on the recent launch of Duet Therapeutics, its wholly-owned subsidiary focused on immuno-oncology Presentation to include a discussion of preclinical data released at the 17th Annual Meeting of the Oligonucleotide Therapeutics Soci
5y agoSCPSScopus BioPharma's Subsidiary — Duet Therapeutics — Announces Release of Preclinical Data Being Presented at 17th Annual Meeting of the Oligonucleotide Therapeutics SocietyGlobeNewswireData from two different studies benchmark Duet's proprietary bifunctional oligonucleotides against immune checkpoint inhibitors ("Checkpoint Inhibitors") in lymphoma and prostate tumor models in mice Studies indicate Duet's bifunctional oligonucleotid
5y agoSCPSScopus BioPharma's Subsidiary — Duet Therapeutics — Set to Release Scientific Data During the 17th Annual Meeting of the Oligonucleotide Therapeutics SocietyGlobeNewswireNEW YORK, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: "SCPS"), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, announced today that Duet
5y agoSCPSScopus BioPharma to Adjourn 2021 Annual Meeting of StockholdersGlobeNewswireNEW YORK, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: "SCPS"), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, announced today that, pur
5y agoSCPSScopus BioPharma to Present at the Benzinga Healthcare Small Cap ConferenceGlobeNewswireNEW YORK, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: "SCPS"), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, today announced it will b
5y agoSCPSScopus BioPharma's Subsidiary — Duet Therapeutics — to Present at the 17th Annual Meeting of the Oligonucleotide Therapeutics SocietyGlobeNewswireAlan Horsager, Ph.D., President and Chief Executive Officer of Duet Therapeutics, will present on CpG-STAT3 RNA Silencing and Antisense inhibitors Presentations to cover CpG-STAT3siRNA (DUET-01) and CpG-STAT3ASO (DUET-02) NEW YORK, Sept. 2
5y agoSCPSChina National Intellectual Property Administration Grants New Patent Covering DUET-02, One of Three Key CpG-STAT3 Inhibitors Comprising the Duet PlatformGlobeNewswireNew patent covers compound and composition and methods of use forCpG-STAT3 Antisense inhibitor (CpG-STAT3ASO) New patent positions Scopus BioPharma's Subsidiary — Duet Therapeutics — to pursue opportunities arising from China's burgeoning biotech
5y agoSCPS XTLBDr. Morris C. Laster Files Preliminary Proxy Statement Nominating Two Highly-Qualified Individuals For Election To Board At Scopus BioPharma Inc.'s 2021 Annual MeetingPR NewswireJERUSALEM, Sept. 20, 2021 /PRNewswire/ -- Dr. Morris C. Laster today announced that he has filed preliminary proxy materials with the Securities and Exchange Commission ("SEC") in connection with the 2021 Annual Meeting of Stockholders ("Annual Meeting"
5y agoSCPSScopus BioPharma's Subsidiary — Duet Therapeutics — Announces Appointments of John Rossi, Ph.D. and Nagy Habib, Ch.M., F.R.C.S. to the Scientific Advisory BoardGlobeNewswireDr. Rossi is a world leader in the development of RNA interference, the Lidow Family Research Endowed Chair and Professor and Chair of the Department of Molecular and Cellular Biology at the Beckman Research Institute of the City of Hope National Medical
5y agoSCPSScopus BioPharma to Present at H.C. Wainwright 23rd Annual Global Investment ConferenceGlobeNewswireNEW YORK, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: "SCPS"), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, today announced it will b
5y agoSCPSScopus BioPharma's Subsidiary — Duet Therapeutics — Announces Appointment of Marcin Kortylewski, Ph.D. as Senior Scientific AdvisorGlobeNewswireDr. Kortylewski is the Leading Authority on Bi-Functional Oligonucleotide Cancer Therapeutics and a Professor in the Department of Immuno-Oncology at the Beckman Research Institute at City of Hope National Medical Center Dr. Kortylewski to Chair a
5y agoSCPSScopus BioPharma's Subsidiary — Duet Therapeutics — to Present at the 14th Annual RNA Consortium MeetingGlobeNewswireNEW YORK, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: "SCPS"), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, today announced that Alan
5y agoSCPSScopus BioPharma Launches Duet TherapeuticsGlobeNewswireDuet Therapeutics Integrates Immunotherapy Assets of Scopus and Olimmune, Acquired by Scopus in June 2021 Integration Creates Comprehensive, Industry-Leading Portfolio of Bi-Functional Cancer-Targeting Oligonucleotides NEW YORK, Sept.
5y agoSCPSScopus BioPharma Announces New Management Appointment Following Acquisition of Leading Immunotherapy CompanyGlobeNewswireNEW YORK, July 12, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: "SCPS"), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical needs, today announced a new man
5y agoSCPSScopus BioPharma Expands Immunotherapy Pipeline with Acquisition of OlimmuneGlobeNewswireTransaction Creates Global Leader in Oligonucleotide Cancer Therapeutics Combined Assets Target Broad Range of Hematological Malignancies and Solid Tumors NEW YORK, June 30, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: "SCPS"),
5y agoSCPSScopus BioPharma Announces New Date for 2021 Annual Meeting of StockholdersGlobeNewswireNEW YORK, May 31, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: "SCPS") today announced that the board of directors has rescheduled the company's 2021 Annual Meeting of Stockholders ("2021 Annual Meeting"), which will be held on October 8, 20
5y agoSCPSScopus BioPharma to Reschedule 2021 Annual Meeting of ShareholdersGlobeNewswireNEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: "SCPS") today announced it will be rescheduling the company's 2021 Annual Meeting of Shareholders (the "2021 Annual Meeting"), which was previously scheduled for July 16, 2021. O
5y agoCVGI PLXP SCPS VSTM+1Thinking about buying stock in Scopus Biopharma, Verastem, Vistagen, PLx Pharma, or Commercial Vehicle?PR NewswireNEW YORK, May 25, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SCPS, VSTM, VTGN, PLXP, and CVGI. To
5y agoSCPSScopus BioPharma Announces FDA Approval of IND Application for Lead Drug CandidateGlobeNewswireCpG-STAT3siRNA is a Distinctive RNA Therapy and Immunotherapy Developed at City of Hope A Phase 1 Clinical Trial Will be Initiated at City of Hope NEW YORK, May 24, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: "SCPS") today announced t
5y agoSCPSScopus BioPharma Announces IND Submission to FDA for Lead Drug CandidatePR NewswireNEW YORK, April 26, 2021 /PRNewswire/ -- Scopus BioPharma Inc. (Nasdaq: "SCPS") today announced the submission of an investigational new drug application ("IND") to the United States Food and Drug Administration ("FDA") for its immuno-oncology RNA therap
5y agoSCPSScopus BioPharma Announces Closing of Underwriters' Over-Allotment Option in FullPR NewswireScopus BioPharma Inc. (Nasdaq: SCPS) today announced the closing of the underwriters' over-allotment option in full, bringing total follow-on public...
5y agoSCPSUnderwriters Exercise Over-Allotment Option in Full, Brings Total Follow-On Public Offering Proceeds to $10.35 MillionPR NewswireScopus BioPharma Inc. (Nasdaq: SCPS) today announced that the underwriters of the company's follow-on public offering exercised their over-allotment...
5y agoSCPSScopus BioPharma Announces Completion of Clinical Lot ManufacturePR NewswireScopus BioPharma Inc. (Nasdaq: SCPS) today announced the completion of clinical lot manufacturing fulfilling the requirements for the planned Phase 1 ...
5y agoSCPSScopus BioPharma Announces Appointment of Additional DirectorsPR NewswireScopus BioPharma Inc. (Nasdaq: SCPS) today announced the appointment of additional members to its Board of Directors. Scopus is a biopharmaceutical...
5y agoSCPSScopus BioPharma Announces Closing of Initial Public OfferingPR NewswireScopus BioPharma Inc. (Nasdaq: SCPS) today announced the closing of its initial public offering. The underwriters for the initial public offering...
5y agoVVOS SCPSBiotech Pair Halted After IPO Craze Triggers Massive RalliesBloombergThe surge in two freshly minted stocks on Thursday triggered trading halts amid a frenzied rush into initial public offerings.
5y agoSCPSScopus BioPharma Announces Pricing of Initial Public OfferingPR NewswireScopus BioPharma Inc. (Nasdaq: SCPS) today announced the pricing of its initial public offering. The company's common stock is set to begin trading...